Key publications

Identification of endothelial-derived proteins in plasma associated with cardiovascular risk
Iglesias MJ, Kruse LD, Sanchez-Rivera L, Enge L, Dusart P, Hong MG, Uhlén M, Renné T, Schwenk JM, Bergstrom G, Odeberg J, Butler LM
medRxiv doi.org/10.1101/2021.02.08.21251209   (2021)

Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage.
Matic LP, Jesus Iglesias M, Vesterlund M, Lengquist M, Hong MG, Saieed S, Sanchez-Rivera L, Berg M, Razuvaev A, Kronqvist M, Lund K, Caidahl K, Gillgren P, Pontén F, Uhlén M, Schwenk JM, Hansson GK, Paulsson-Berne G, Fagman E, Roy J, Hultgren R, Bergström G, Lehtiö J, Odeberg J*, Hedin U*.
JACC: Basic to Translational Science Aug 2018, PMID: 30175270

Analysis of Body-wide Unfractionated Tissue Data to Identify a Core Human Endothelial Transcriptome.
Butler LM, Hallström BM, Fagerberg L, Pontén F, Uhlén M, Renné T, Odeberg J.
Cell Systems. 2016 Sep 28;3(3):287-301.e3.

PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study.
Bruzelius M, Iglesias MJ, Hong MG, Sanchez-Rivera L, Gyorgy B, Souto JC, Frånberg M, Fredolini C, Strawbridge RJ, Holmström M, Hamsten A, Uhlén M, Silveira A, Soria JM, Smadja DM, Butler LM, Schwenk JM, Morange PE, Trégouët DA, Odeberg J.
Blood. 2016;128(23):e59-e66 PMID:27742707

Predicting venous thrombosis in women using a combination of genetic markers and clinical risk factors.
Bruzelius M, Bottai M, Sabater-Lleal M, Strawbridge RJ, Bergendal A, Silveira A, Sundström A, Kieler H, Hamsten A, Odeberg J.
Journal of Thrombosis and Haemostasis 2015;13(2):219-27

Jacob Odeberg

Principal investigator (PI)
Professor in Clinically Applied Proteomics 
Consultant in Hematology and Internal medicine
Science for Life Laboratory, Department of Protein Sciences, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Royal Institute of Technology (KTH)

Research interests

Clinically applied proteomics 
We use high throughput proteomic approaches to study the protein composition of blood plasma from patients with cardiovascular and thromboembolic disorders.

More recently, this has also included patients with COVID-19. The aim is to identify novel protein biomarkers for clinical application in risk prediction, diagnosis and long term prognosis. We are also interested in the study of genetic susceptibility to cardiovascular disease and venous thromboembolism, especially gene regulatory mechanisms and how genetic variation can affect protein expression. 

Group members

Maria Jesus Iglesias, Senior Researcher 
Philip Smith, PhD Student 
Jeong Yeon Kim, Post Doc

Contact

jacob.odeberg@scilifelab.se

Last updated: 2022-11-30

Content Responsible: admin(website@scilifelab.se)